Good day, and welcome to IM Cannabis' Third Quarter 2022 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Maya Lustig, Director of Investor and Public Relations. Please go ahead. Thank you, operator. Joining me today are IM Cannabis Chief Executive Officer, Oren Shuster, and Chief Financial Officer, Shai Shemesh. The earnings release that accompanies this call is available on the investor relations section of our website at investors.imcannabis.com. Today's call will include estimates and other forward-looking information and statements, including statements concerning future revenues, results from operations, financial positions, markets, economic conditions, product releases, partnerships, and any other statements that may be construed as a prediction of future performance. The information may involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Furthermore, certain non-IFRS measures will be referred to during this call. The company believes that the presentation of this non-IFRS information provides useful supplementary data concerning the company's ongoing operation and is provided for informational purposes only. Any estimates or forward-looking information or statements provided are accurate only as of the date of this call, and the company undertakes no obligation to publicly update any forward-looking information or statements or supply new information regarding the circumstances after the date of this call. Please note that all references on this call reflect currency in Canadian dollars. With that, it is my pleasure to turn the call over to Oren Shuster, CEO of IM Cannabis. Oren, please go ahead. Thank you, Maya. Good morning, everyone, and thank you for joining us today. The third quarter marked a pivotal point for us. As part of our Canadian restructuring efforts to achieve operational efficiencies, we commenced our exit from the Canadian market to move closer to our goals of growth and profitability. This route was chosen only after exhausting all other options, including the exploration of potential sale of some or all of the Canadian operations. As part of this decision, we are not providing any funding to the Trichome Group any longer. In parallel, we have been able to reduce the company's debt substantially. We believe that the CCAA decision eventually made by the Trichome Group supports the long-term interest of our shareholders and the company. For those of you less familiar with the Canadian CCAA proceedings, allow me to provide a brief explanation. CCAA allows the Trichome Group to carry on its business in Canada under the protection of the Canadian court. The Trichome Group intends to use the CCAA proceedings to implement a sale and investment solicitation process for the sale of its assets or restructuring of its business. The Trichome Group continues to operate its business for the time being. I would like to make it clear that this process is limited only to Trichome Group, meaning none of our assets or subsidiaries in Israel or Germany are involved in the CCAA proceedings. As Shai will explain later in the call, our financials include the company's results from continuing operations. The activities of Trichome Group are collectively referred to as the discontinued operations. Let me state that there is no change to the company's U.S. and Canadian listings on the NASDAQ and the CSE. Unloading our Canadian division demonstrates our focus and commitment to profitability and growth. We believe we will be able to return value to our investors. We also anticipate that we will further optimize and synergize our existing international operations, as well as concentrate our resources where we see the most potential. We are a new company today with a sharper focus, and we will use today's call to help our investors understand what we see on the horizon and what we are doing on the ground together. Immediately in front of us is a transition period which may prove challenging, but it is designed to lead us to stronger results. I'm pleased to share that we will now direct more resources and efforts into where we believe will grow the fastest, namely Israel, and to grow where we see significant potential, namely Germany. The third quarter was successful in many respects. We signed an international trademark licensing agreement with the Avant Brands, granting us the exclusive right to launch the Black Market brand in Israel. This agreement will allow us to introduce to Israeli medical cannabis patients a new variety of quality ultra-premium brands. In addition, during the quarter, our partner Sundial completed its initial international export of approximately 167 kgs of premium dried flower from Canada to Israel. This was only one part of their total commitment with us, which is 1,000 kgs. I will now provide an overview of each of our market segments. After this overview, Shai will review our financial results before we open the call up for questions. In Israel, our reputation as a leading premium and ultra-premium provider is on the rise, bolstering our competitive power in the Israeli market. We were early movers in the premium and ultra-premium product categories in the Israeli medical cannabis market, and we continue to lead this market segment. Our strong focus on the premium and ultra-premium segments allows us to increase our prices. As a matter of fact, there has been 37% increase in the price per gram, currently selling at approximately CAD 9.1 per gram compared to an average selling price of approximately CAD 6.6 per gram last year. We believe that our average selling price is the highest in Israel. Shai will elaborate on this further. In August this year, our legacy strain, Roma, was voted as the favorite strain of the month by Cannabis, a leading cannabis blog for the Israeli medical patients. Positive patient feedback is critical element in pharmacies high interest in working with us. They look forward to IMC product news as our strains perform strongly, offering pharmacies a quick inventory rotation at premium prices. In Israel, we continue to build strong brand portfolio and a superior product offering. In Q3, we introduced the Top-Shelf Collection, our newest addition to IMC's brand portfolio. We launched it in September 2022 as a premium product line with indoor-grown high-THC cannabis flowers. The Top-Shelf Collection offers strains such as Lemon Rocket and Diesel Drift. This collection targets the growing recreational-leaning market segment of medical patients. In addition, as part of our Craft Collection, which is our ultra-premium indoor-grown product line, we introduced a new strain, Watermelon Zkittlez, which has seen strong patient demand since it's launched. The future holds strong potential for us. With the Avant Brands shipment agreement, we will also be introducing the Black Market brand in Israel, and we expect great results from this brand's product offering. We also expect to generally see increased potential political and economic stability in Israel as the elections are behind us, and we are likely to have long-term government in office. In the third quarter, we continued to place a strong focus on efficiency and synergies in our Israeli operations. In the second quarter, we merged two large call centers into the largest center in Israel, which in the third quarter, started to create cost reductions as well as consistency and expertise in providing service to patients. To date, we established robust global supply infrastructure through our strong relationships with suppliers and partners. Our network of European and Canadian suppliers include world-leading names as Avant Brands, Sundial, and others, giving us a key competitive advantage in Israel. We also source quality medical cannabis from local Israeli-based cultivators and suppliers. Our sourcing network allow us to offer patients the premium and ultra-premium experience they have come to expect from IM Cannabis. Our success in Israel give us confidence, and we strongly believe that this success can be replicated in Germany. As we wait for the proposed legalization of recreational cannabis use in Germany, in the third quarter, we were pleased to see a steady increase in self-paying patients who can easily get prescription and access high-quality medical cannabis products. We also see a steady increase in the number of teleclinics and online pharmacies that are becoming available to medical cannabis patients. In October, the German government unveiled plans for legalization of recreational cannabis for adults. Many details will need to be worked out locally and with the E.U. before legalization is passed. The German Health Minister has commented that if everything were to go well, legalization could be achieved as early as 2024. We strongly believe that German legalization will pave the way for legalization in other European countries such as Italy, Spain, France, and the U.K. Our goal is to develop strong foothold in the EU market, create an early mover advantage, and drive significant market share. We are now much more focused and streamlined company. Israel and Germany have much in common, such as a strong and well-organized medical cannabis sector that distributes cannabis through pharmacies operating under the relevant GMP and EU GMP standards. There is also high consumer demand for premium and ultra premium cannabis and a robust commercial infrastructure in both markets. In our view, these common points, plus our strong sourcing infrastructure, give us a key competitive advantages in Germany. We will be allocating the needed capital and efforts to further establish our presence in Israel and Germany and to achieve profitability. I will now turn the call over to our Chief Financial Officer, Shai Shemesh, who will review our third quarter 2022 financial results. Shai? Thank you, Oren. As mentioned at the beginning of the call, during September 2022, the company decided to commence its exit from Canada and is no longer providing any funding to the Trichome Group. The decision was based on an anticipated significant change in the competitive landscape in Canada, as well as the company's revamped growth strategy. In Q3 2022 financials, the Trichome Group is classified as held for sale in the consolidated statement of financial position and as discontinued operations in the consolidated statement of comprehensive income and statement of cash flows for all periods presented. I will now provide an overview of our Q3 2022 financial results for the company's continuing operations. Revenues for Q3 2022 were CAD 14.2 million compared to CAD 8 million in Q3 2021, an increase of 78%, representing a 12% sequential organic growth. The increase in revenues is primarily attributed to the increase in the quantity of medical cannabis products sold, as well as from the higher average selling price per gram the company realized from its portfolio of premium and ultra premium branded cannabis products in Israel. The company sold 1,453 kilograms of dried flowers in Q3 2022 at an average selling price of CAD 9.08 per gram, compared to 1,175 kilograms for the same period in 2021 at an average selling price of CAD 6.61 per gram. The change in our average selling price reflects a 37% increase. Gross profit before fair value adjustment in Q3 2022 was CAD 2.8 million compared to CAD 2 million in Q3 2021. Gross margin for Q3 2022 was 20% compared to 25% in Q3 2021. The decrease is mainly attributed to an expired local non-premium inventory write-offs. General and administrative expenses in Q3 2022 were CAD 4.3 million compared to CAD 3.7 million in Q3 2021. The increase is mainly attributable to increase in professional and legal services. Sales and marketing expenses in Q3 2022 were CAD 2.8 million compared to CAD 1.7 million in Q3 2021. The increase is mainly attributed to the company's intensified marketing efforts in Israel, brand launch in Germany, higher distribution expenses, and increased staffing from acquisition, all in line with our expectations. Total operating expenses in Q3 2022 were CAD 7.5 million compared to CAD 8 million in Q3 2021. Operating loss for Q3 2022 was CAD 5.5 million compared to CAD 8.1 million in Q3 2021. Non-IFRS adjusted EBITDA loss from continuing operations in Q3 2022 was CAD 3.7 million compared to an adjusted EBITDA loss of CAD 2.3 million in Q3 2021. The increase is mainly attributable to corporate expenses and related legal expenses in connection with the company's exit from the Canadian market. Net loss from continuing operations for Q3 2022 was CAD 4.5 million compared with net income of CAD 0.8 million in Q3 2021. Basic loss per share attributable to equity holders of the company from continuing operations was CAD 0.6 compared to basic earnings per share of CAD 0.03 in Q3 2021. Diluted loss per share attributable to equity holders of the company from continuing operations was CAD 0.6 compared to diluted loss per share of CAD 0.09 in Q3 2021. Net loss from discontinued operations for Q3 2022 was CAD 123.6 million compared with a loss of CAD 6.5 million in Q3 2021. The difference is mainly attributable to CAD 115.1 million impairment related to the company's discontinued operations. Basic and diluted loss per share attributable to equity holders of the company from discontinued operations was CAD 1.75 compared to basic and diluted loss per share of CAD 0.1 in Q3 2021. As of September 30, 2022, the company's cash position from continuing operations was CAD 3.2 million, and its working capital from continuing operation was CAD 10.3 million. As Oren mentioned, by commencing the exit from the Canadian market, we have been able to reduce the company's debt levels substantially. Debt from continuing operations for September 30, 2022 was CAD 5.1 million, representing a decrease of approximately 57%. The company is planning to finance its operations from its existing and future working capital resources, use of available credit facilities, and will continue to evaluate additional sources of capital and financing as needed. In addition to our financial results, the company also announced today that it plans to implement a 10-for-1 share consolidation of its common shares, expected to be effective on or around November 17, 2022. The purpose of the consolidation is to regain compliance with NASDAQ minimum bid price requirements. I would now like to turn the call back to Oren for closing remarks. Oren? Thank you, Shai. We will continue to concentrate our efforts on our highest value markets, Israel and Germany, and accelerate our path to profitability. Today, we are seeking to maximize efficiency and create the right balance for future success. We are further strengthening our Israeli operations and preparing to bring our expertise to Europe to achieve market leadership in the medical cannabis market and to be fully ready to capitalize on the German recreational cannabis market upon legalization. With that, I hand the call over to the operator to begin our question and answer session. Operator? Thank you. In order to ask a question, please raise your hand using your mobile or desktop application and wait for your name to be announced. Once again, please raise your hand using your mobile or desktop application and wait for your name to be announced. Our first question today comes from the line of Aaron Grey from Alliance Global Partners. Please go ahead. Hi, good morning, and thank you for the questions. So first question for me, want to talk a little bit more about Israel. You know, first, also nice growth sequentially there. Could you talk about the split between retail and wholesale packs? I know you've had, you know, a verticality initiative going on there. More broadly speaking, you know, a number of competitors have called out obviously pricing pressure and a slowdown in the market, you know, even pulling back from, you know, exporting most of the Canadian LPs to the market, at least in the interim. You guys spoke to your premium positioning. Can you talk about how you're seeing the competitive environment, maybe how you guys see yourself as differentiated versus some of the other, you know, competitors who might be seeing more pressure there, and how you see the market evolving going forward? Thanks. Okay, thanks. Hi, good morning, and hi, everybody. So IMC actually opened a new category in Israel, which is the premium and the ultra-premium, and we have been the first one to start with that. I think that we have built a leading position in this segment in the Israeli market. I think that it's reflected very well in our average selling price that went up significantly to about CAD 9.1 per gram in Israel, on average, I think in Israel. In Germany, and I think that it means a lot. Last year in the same quarter, we've been at CAD 6.6. I think that that's the reflection of moving to the premium segment. I think that it says a lot about the price pressure because we don't feel this price pressure in our segment, in the premium segment. Okay, great. That's helpful. About the verticality split between retail and wholesale for Israel? When you speak, you mean what is the split between them? Yeah. Like just progress in terms of what you were selling through your own stores versus what you're selling through third-party retailers. Yeah. Cause I know you're gonna start selling more of your own product in your own stores, you know, with those acquisitions that have closed. Yeah. Most of the product that IMC sold wasn't in our pharmacies. We are improving all the time. It's a process. I think that we are enlarging our portion in our pharmacies from quarter to quarter. You know, we have a network of partners. We don't want to focus only on our stores because the market is growing all the time, and we have to supply our partners as well. Okay, great. That's a powerful color. Next question for me. Want to talk a little more about Germany, regarding some of the details that the health minister provided, particularly around, you know, keeping production domestic. You know, for IMC, you know, what are your thoughts on them being able to, you know, produce it domestically and being able to meet demand within Germany, especially with that 2024 potential target? How would IMC look to participate in the market, you know, if they were to hold that, you know, excluding exports, you know, from the market? How would you guys look to then compete within the German adult use opportunity? Thank you. I think that the German market is definitely the most interesting opportunity today. On the other side, I think that it will take time before the market will be mature, actually a lot of time. To grow a high-quality cannabis, it's a process. It's not something that happens in one day. I think that it will take time to build the industry in Germany. I think that the industry that Germany will stay an import market for years, definitely, well after the legalization will start because there is the channel of the medical cannabis, and I think that the channel of medical cannabis will be the channel for high quality product, still after legalization. As of now, this is what we are focusing in. We will see the final regulations in Germany, and then we will take decisions according to that. I think that it's very early, and I think that the regulations are going to change significantly from the draft that was published. Okay. All right. Thanks so much. Last question from me. Just you talked about, you know, that path to profitability, you know, saw some improvement sequentially, especially when you look at it, excluding the discontinued operations. Any additional color you might be able to provide in terms of, you know, the timing to reach profitability and maybe how we look at the gross margin, you know, versus the SG&A, in terms of how we look to model it out to reach that. Thank you. Okay. Thank you. I will start, and Shai will maybe add some more color. We think that in Q1 we will reach a positive cash flow and definitely profitability. The business now is much simpler. Definitely, I feel that we are in a better position with significantly lower debt position. Shai will continue maybe the rest. Yeah. Hi, Aaron. How are you? About the gross margin, yes, we had around 20% gross margin in Q3. We definitely expect it to increase in the coming quarters. In the past, I said that we are aiming more than the 30% gross margin. We are still talking about that. That's it. This is the area. We want to go around 35%, at least. This is where we're aiming. We have a difference between the trade and the retail. We're talking about two different gross margins environments, but on average, we expect to be above the 30%. All right, great. Thank you very much for the color. I'll jump back in the queue. Thank you. As a reminder, if you wish to ask a question, please raise your hand using your mobile or desktop application and wait for your name to be announced. Our next call will come from the line of Scott Fortune from Roth Capital. Please go ahead. Scott, are you able to unmute? Yes, sir. Sorry about that. Good morning or evening from where you are. Just want to get a sense for what you're seeing on the patient growth side in Israel. I know we saw some sort of stabilization, but your sense for the growth kind of continuing for Israel and the medical market going forward here? Hi, Scott. Good morning. We have seen that the market is growing constantly. There was a delay a few months ago, but lately we've seen that we are coming back to about 2% on a monthly basis, growth pace. That's the situation as of now. Before any change in the regulations, I don't see any reason that it will go down this growth pace. Got it. Just wanna follow up a little bit more color. I know you're putting a lot of focus on the premium and ultra side as you build that out in Israel. Can you kind of quantify that for us as a percentage of the overall cannabis market in Israel? Where do you think it can be at? As far as your market share, I know you're the kind of leader there, but kind of the market share from the overall premium side for IMC I see here. It's a very good question. I think that in that sense, Israel is very different than other places because of the situation that the black market is more expensive than the medical market. I think that the demand for premium products is higher than in other places because we're speaking about the medical market, that actually there is a leakage to the black market, especially of high-quality products. I don't know exactly what is the size of the market, but what I know is that we are very far from exhausting the potential. What we see is whatever we are bringing, if it's premium, it doesn't matter the price, it's sold out immediately. That's great. As far as your supply sources now that you've kind of shuttered the Canadian business, will you be looking to continue to add supply? What kind of levels of supply are you at to fulfill the business there? I'll jump back in the queue. We build a supply chain actually with a few partners that we're working with them very well. Next year we are going to increase this cooperation and to increase the quantities that we are bringing into the market. We have done it in a very responsible way. We started to build the category with smaller quantities, and we have a plan. We are enlarging the quantities quarter-over-quarter. We don't want to flood the market, and it's we have built it very responsibly, the segment. What we will see is increase in quantities, and we will do it responsibly. This is that's my forecast. I appreciate the color. Thank you. Thank you. Thank you. You have no further questions. Please proceed. Thank you, operator, and thank you all for joining our call today. Please continue to track our progress as we continue to execute on our growth strategy, and I look forward to speaking with you in the coming quarters. I'm also happy to set a meeting with you. If you wish to talk, please send an email to IMC's IR director, Maya Lustig, and she will be happy to assist. Thank you very much.